ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients
ARIAD Pharmaceuticals, Inc. announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met...
Cook Medical’s Ongoing Drug-Eluting Peripheral Stent Trial Shows Consistent Outcomes
An investigational drug-eluting stent (DES) from Cook Medical showed sustained primary patency at two years...
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes...
Boehringer Ingelheim and Eli Lilly and Company announced a global agreement to jointly develop and...
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse Capsules
Shire plc, the global specialty biopharmaceutical company, today announced results from a study of Vyvanse®,...
Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab
Sandoz announced today that it has begun a phase II clinical trial in patients for...
Whats on the horizon for pharma sales- a look to the year ahead from...
eyeforpharma recently interviewed: Hans Hoogkamer, Business and Science Affairs, Actelion Pharmaceuticals, Daniel Ghozzi, Managing Director...
Merck Expand Study Investigating Erbitux as 1st Line Treatment in Advanced Gastric Cancer Completes...
Merck KGaA announced that recruitment has been completed for the pivotal Phase III EXPAND(a) clinical...
KOMBIGLYZE XR Tablets, a New Treatment for Type 2 Diabetes Mellitus in Adults, Now...
Bristol-Myers Squibb Company and AstraZeneca announced that KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release), approved...
NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422 Against Deadly Superbug
NovaBay Pharmaceuticals, a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and...
Lundbeck phase III studies confirm nalmefene as efficacious and safe in helping individuals to...
H. Lundbeck A/S (Lundbeck) announced the completion of two out of three pivotal studies in...
